Search
Dexchlorpheniramine maleate
go.drugbank.com/drugs/DB09555ApprovedDexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. … Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
Mixtures: Re Drylex, Corzall PECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsGuanadrel
go.drugbank.com/drugs/DB00226ApprovedGuanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Thrombomodulin Alfa
go.drugbank.com/drugs/DB05777ApprovedThrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). … It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular
Novobiocin
go.drugbank.com/drugs/DB01051ApprovedInvestigationalVet approvedWithdrawn(From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious … Novobiocin is an antibiotic compound derived from _Streptomyces niveus_. It has a chemical structure similar to coumarin.
Synonyms: N-{7-[(3-O-carbamoyl-6-deoxy-5-methyl-4-O-methyl-β-D-gulopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl}-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamideCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingReboxetine
go.drugbank.com/drugs/DB00234ApprovedInvestigationalWithdrawnReboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. … Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: เอ็ดโดรแน็กซ์ (4 มก.), Edronax 4 mg - TablettenGalantamine
go.drugbank.com/drugs/DB00674ApprovedInvestigationalGalantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease … [L13571] It is therefore not considered to be a disease-modifying drug.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: REMINYL ®ER CAPSULAS DE 8 MG, REMINYL ® ER CAPSULAS DE 16 MGArdeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnNormiflo was withdrawn from the US market in March 2000. … Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.
Sapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationalSapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingSynonyms: 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone, (−)-(6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinoneAndusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigationalAndusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. … [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Fedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. … [A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]
Categories: MATE 1 Inhibitors, MATE 2 Inhibitors